St. Jude Children’s Research Hospital shared on LinkedIn:
“Advances in genomics, molecular profiling and computational biology are changing how pediatric cancers are understood.
Increasingly, diagnosis provides more than an explanation about the disease itself. It offers insight into how cancer may behave, how a patient may respond to treatment, and what health challenges may emerge later in life.
St. Jude researchers including Lu Wang, MD, PhD; Xin Zhou, PhD; Giles Robinson, MD; Ching-Hon Pui, MD; and Matt Ehrhardt, MD, MS, among others, are helping translate those discoveries into more personalized approaches to risk assessment, allowing clinicians to tailor care based on the unique characteristics of each patient and disease.
‘Risk assessment is fundamental to improving therapy,’
– Robinson said.
‘While cancer therapy has advanced, many curative treatments still rely on highly toxic and nonspecific therapies that take a huge toll on children.’
By integrating genomic discoveries, treatment response data and survivorship research into clinical decision-making, St. Jude is tailoring cancer treatment upon diagnosis to secure the best outcomes for patients while minimizing toxicity as much as possible.”
Other articles about St. Jude Children’s Research Hospital on OncoDaily.